MG
CEMI

Michael Gelband’s Chembio diagnostics, Inc. CEMI Stock Holding History

Michael Gelband’s Portfolio CEMI Stock Details CEMI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,672
Closed -$32K – 2939
2021
Q2 		$32K Buy
+10,672
New +$37.2K ﹤0.01% 2246

Other funds holding CEMI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $8.43B AUM 52.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $5.32B AUM 30.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Michael Gelband's CEMI Position: Q3 2021 in Review

Michael Gelband sold out of Chembio diagnostics, Inc. (CEMI) in Q3 2021, closing a stake of 10,672 shares — an estimated $32K sold.

Michael Gelband first reported a position in CEMI in Q2 2021 and held it in 1 quarter. The position peaked at $32K in Q2 2021. 47 funds tracked by Wall St. Rank hold CEMI as of Q3 2021.

  • Michael Gelband reported no remaining Chembio diagnostics, Inc. position as of Q3 2021 after selling out during the quarter.
  • Michael Gelband sold 10,672 Chembio diagnostics, Inc. shares in Q3 2021, an estimated $32K.
  • Michael Gelband first reported a position in Chembio diagnostics, Inc. in Q2 2021 and held it in 1 quarter.
  • Michael Gelband's Chembio diagnostics, Inc. position peaked at $32K in Q2 2021.
  • 47 funds tracked by Wall St. Rank held Chembio diagnostics, Inc. as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.